Celltrion Holds Omriclo Launch Event in Brazil, Accelerates Expansion into Latin American Market
Over 80 Brazilian Healthcare Professionals Attend Event
Successful Bid Secured from Santa Catarina State Government
Celltrion announced on March 31 that it has held a launch event in Brazil, the largest pharmaceutical market in Latin America, for its autoimmune disease treatment, Omriclo (active ingredient: omalizumab).
More than 80 participants attended the event, including allergy, respiratory, and dermatology specialists, as well as representatives from insurance companies in Brazil. The event covered Omriclo's clinical data, global prescription experience, and its value in real-world clinical settings. Attendees expressed great interest in case studies of Omriclo prescriptions and showed anticipation for the drug's expanded use in the future.
Key opinion leaders from around the world participated as speakers, including Dr. Pedro Giavina Bianchi and Dr. Rosana Agondi, allergy and immunology specialists at the University of Sao Paulo (USP) School of Medicine Hospital, as well as Professor Adam Reich, a dermatologist at the University of Rzeszów in Poland who participated in Omriclo's global Phase 3 clinical trial. They shared the latest medical information focused on key data such as results from Omriclo's global Phase 3 clinical trial, the role of omalizumab in treating asthma and chronic spontaneous urticaria, and the scientific principles and clinical significance of biosimilars.
Through this launch event, Celltrion strengthened its network with influential medical professionals in Brazil and enhanced trust in its products. With support from local key opinion leaders, the company expects the expansion of Omriclo prescriptions in Brazil to accelerate further.
Since Celltrion Brazil launched Omriclo in November last year, it has continued local marketing activities and recently secured early supply channels by successfully winning a bid from the Santa Catarina state government. In particular, as Omriclo was introduced as a first mover in Brazil, the effect of early market entry is expected to be maximized, with additional bidding successes likely to follow.
Brazil, which accounts for half of the pharmaceutical market in Latin America and has a population of over 210 million, is recognized as a major country with both market potential and symbolic significance. Celltrion continues to achieve strong sales in Brazil with its key products. In the local private market, Truxima (active ingredient: rituximab) holds a market share of about 40%, and Remsima (active ingredient: infliximab) about 60%, leading the market.
Building on the sales performance of its existing products, Celltrion aims to increase the market share in Brazil for Omriclo and other subsequent products, while further expanding its product portfolio across the entire Latin American region to solidify its market influence on the continent.
Latin America, a representative “Pharmerging” market, is experiencing pharmaceutical industry growth at an average annual rate of about 7%. With its large population and the ongoing advancement of the healthcare industry, the region is considered a high-potential market.
Celltrion has been steadily strengthening its presence as a leading biosimilar company in Latin America. As a result, it has consistently secured annual tenders in countries such as Costa Rica (Herzuma 95%, Truxima 95%), Ecuador (Herzuma 85%, Truxima 84%), the Dominican Republic (Remsima 94%, Herzuma 83%, Truxima 83%), Guatemala (Truxima 70%), and Paraguay (Remsima 50%). Celltrion’s Latin America branch plans to leverage its established human network, built through sales of existing products, to drive further success with high-value new products.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kang Kyungdu, Head of the Latin America Division at Celltrion, stated, "Key healthcare professionals in Brazil who attended this launch event showed strong interest and positive responses toward Omriclo. We expect that the network built through these interactions will serve as a foundation for expanding prescriptions in the future. With our success in securing state government tenders early on, demonstrating our strength as a first mover, we will work to further increase our bidding achievements in Brazil and expand Omriclo’s launch across Latin America to solidify our market influence."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.